What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
Glaukos secures a permanent J-code for Epioxa. Read why this reimbursement milestone could shape keratoconus treatment adoption and payer access.
Is Glaukos building a multi-franchise ophthalmology platform through Epioxa and glaucoma implants?
Glaukos heads to ASCRS 2026 with Epioxa and glaucoma data. Read what this could change for keratoconus, sustained therapy, and adoption.